Online inquiry

IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3452MR)

This product GTTS-WQ3452MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3452MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12339MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ2057MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ6584MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ1492MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ2116MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ9388MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ12577MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ14194MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW